IMAGE: IBA-1 staining reveals heavy microglial infiltration in SHH MB with many microglia co-expressing PD-L1. Immunohistochemistry of one representative SHH MB, 18872, stained for IBA-1 (A) and PD-L1 (B). Many of… view more
Credit: Allison M. Martin at firstname.lastname@example.org
This study evaluated the expression of PD-L1 and markers of immune mediated resistance in human medulloblastoma, the most common malignant pediatric brain tumor.
In cell lines, SHH MB, which are low-MYC expressing, demonstrated both constitutive and inducible expression of PD-L1 while those in Group 3/4 that expressed high levels of MYC had only inducible expression.
MB expresses low levels of PD-L1 facilitating immune escape.
“Tumors in the SHH subgroup are characterized by genetic alterations activating this key developmental pathway. WNT subgroup tumors have alterations in the wingless/ -catenin developmental pathway.”
Most patients are assessed for PD-L1 expression prior to starting therapy, but the expression of PD-L1 during the entire course of treatment remains unclear, as does the relationship between changing PD-L1 expression and therapeutic responses.
In support of PD-L1 pathway activity in human MB, the researchers demonstrated that MB cell lines robustly up-regulated PD-L1 when they simulated an anti-tumor immune response in vitro by exposing the cell lines to recombinant
Article originally posted at